Results 141 to 150 of about 38,526 (184)

Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study. [PDF]

Ann Med
Zheng W, Zhou M, Xing Y, Zhao J, Liu B, Li W, Sun S.   +6 more
europepmc   +1 more source

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study. [PDF]

Ann Hematol
Wang Y, Chen X, Liang Q, Wang W, Luo J, Luo L, Feng R, Wei Y, Tian Y, Du X, Huang Z, Hu G, Fu X, Tao S, Zhou J, Peng H, Su Y, Zhang H, Dong M, Lan M, Sun Z, Wang X, Zhou H, Zhong L, Peter Gale R, Liang Y, Xia Z.   +26 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bortezomib

Reactions Weekly, 2009
The ubiquitin-mediated degradation of proteins in numerous cellular processes, such as turnover and quality control of proteins, cell cycle and apoptosis, transcription and cell signaling, immune response and antigen presentation, and inflammation and development makes the ubiquitin-proteosome systems a very interesting target for various therapeutic ...
  +8 more sources

Bortezomib

Nature Reviews Drug Discovery, 2003
Andrew, Paramore, Simon, Frantz
openaire   +4 more sources

Bortezomib

DMW - Deutsche Medizinische Wochenschrift, 2006
S, Simons, M E, Scheulen, U, Jaehde
openaire   +3 more sources

Bortezomib

Reactions Weekly, 2020
  +5 more sources

Bortezomib

Reactions Weekly, 2007
  +4 more sources